Publication

Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Oya, M.
; 
Armstrong, A. J.
; 
Thiery-Vuillemin, A.
; 
Shore, N.
; 
Procopio, G.
; 
Arslan, C.
; 
Mehra, N.
; 
Parnis, F.
; 
Brown, E.
; 
Schlurmann, F. C.
... show 9 more
Citations
Altmetric:
Abstract
Authors
Oya, M.
Armstrong, A. J.
Thiery-Vuillemin, A.
Shore, N.
Procopio, G.
Arslan, C.
Mehra, N.
Parnis, F.
Brown, E.
Schlurmann, F. C.
Joung, J. Y.
Sugimoto, M.
Sartor, O.
Liu, Y. Z.
Poehlein, C. H.
Desai, C.
Del Rosario, P. M. D.
Clarke, Noel W
Saad, F.
Affiliation
Department of Urology, Keio University School of Medicine, Shinjuku-ku, Japan
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Oya M, Armstrong AJ, Thiery-Vuillemin A, Shore N, Procopio G, Arslan C, et al. Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 2022 Nov;38(9):S1495-S. PubMed PMID: WOS:000897943700159.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626139
Embedded videos